A phase I/II trial of melphalan (MEL) combined with panobinostat (PAN) for patients with relapsed or refractory (R/R) multiple myeloma (MM).Ori Yellin, Robert Vescio, Ralph V. Boccia et al.|Journal of Clinical Oncology|2012Cited by 6